CA2113272A1 - Methode de traitement du sida par l'amphotericine b a toxicite reduite - Google Patents

Methode de traitement du sida par l'amphotericine b a toxicite reduite

Info

Publication number: CA2113272A1
Authority: CA; Canada
Prior art keywords: hiv; ion; amphotericin; ate; teryl
Prior art date: 1991-08-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002113272A

Other languages

English (en)

Inventor

Francis J. Martin

Martin C. Woodle

Luke S. S. Guo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alza Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-14

Filing date

1992-08-12

Publication date

1993-03-04

1992-08-12 Application filed by Individual filed Critical Individual

1993-03-04 Publication of CA2113272A1 publication Critical patent/CA2113272A1/fr

Status Abandoned legal-status Critical Current

Links

APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 title claims abstract description 33
238000000034 method Methods 0.000 title claims abstract description 27
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 title claims abstract description 16
229960003942 amphotericin b Drugs 0.000 title claims abstract description 16
238000011282 treatment Methods 0.000 title claims description 5
231100000053 low toxicity Toxicity 0.000 title 1
239000002245 particle Substances 0.000 claims abstract description 68
239000000203 mixture Substances 0.000 claims abstract description 37
210000004027 cell Anatomy 0.000 claims abstract description 32
BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims abstract description 23
229940080277 cholesteryl sulfate Drugs 0.000 claims abstract description 23
210000002540 macrophage Anatomy 0.000 claims abstract description 15
208000031886 HIV Infections Diseases 0.000 claims abstract description 10
208000037357 HIV infectious disease Diseases 0.000 claims abstract description 8
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 8
230000002401 inhibitory effect Effects 0.000 claims abstract description 6
230000005764 inhibitory process Effects 0.000 claims abstract description 5
210000005259 peripheral blood Anatomy 0.000 claims abstract description 4
239000011886 peripheral blood Substances 0.000 claims abstract description 4
108010027044 HIV Core Protein p24 Proteins 0.000 claims abstract 2
239000006185 dispersion Substances 0.000 claims description 36
239000000427 antigen Substances 0.000 claims description 8
102000036639 antigens Human genes 0.000 claims description 8
108091007433 antigens Proteins 0.000 claims description 8
230000000694 effects Effects 0.000 claims description 8
239000000725 suspension Substances 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 7
210000004698 lymphocyte Anatomy 0.000 claims description 4
239000000463 material Substances 0.000 claims description 3
239000012736 aqueous medium Substances 0.000 claims description 2
230000006378 damage Effects 0.000 claims description 2
230000003836 peripheral circulation Effects 0.000 claims description 2
102100034343 Integrase Human genes 0.000 claims 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
239000002577 cryoprotective agent Substances 0.000 claims 1
230000000737 periodic effect Effects 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
150000002500 ions Chemical class 0.000 description 132
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 47
239000003814 drug Substances 0.000 description 37
229940079593 drug Drugs 0.000 description 37
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 36
241001465754 Metazoa Species 0.000 description 27
241000700159 Rattus Species 0.000 description 21
QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 19
241000282472 Canis lupus familiaris Species 0.000 description 17
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfate Natural products OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 17
238000002347 injection Methods 0.000 description 16
239000007924 injection Substances 0.000 description 16
231100000419 toxicity Toxicity 0.000 description 16
230000001988 toxicity Effects 0.000 description 16
150000002632 lipids Chemical class 0.000 description 15
210000002381 plasma Anatomy 0.000 description 15
231100000331 toxic Toxicity 0.000 description 15
230000002588 toxic effect Effects 0.000 description 15
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
238000009472 formulation Methods 0.000 description 13
239000002609 medium Substances 0.000 description 13
235000012000 cholesterol Nutrition 0.000 description 12
229940107161 cholesterol Drugs 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
208000015181 infectious disease Diseases 0.000 description 10
239000012071 phase Substances 0.000 description 10
230000003612 virological effect Effects 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
210000004185 liver Anatomy 0.000 description 9
210000000056 organ Anatomy 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
108010039491 Ricin Proteins 0.000 description 8
-1 cholesteryl sulf Chemical compound 0.000 description 8
239000000523 sample Substances 0.000 description 8
ULRQJNITUNNDBO-UHFFFAOYSA-N Steryl sulfate Chemical compound C1CC2C3CCC(OS(=O)(=O)O)CC3CCC2C2CCCC21 ULRQJNITUNNDBO-UHFFFAOYSA-N 0.000 description 7
238000001802 infusion Methods 0.000 description 7
239000002502 liposome Substances 0.000 description 7
230000007170 pathology Effects 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
229930182558 Sterol Natural products 0.000 description 6
238000007792 addition Methods 0.000 description 6
230000037396 body weight Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
210000002700 urine Anatomy 0.000 description 6
241000700605 Viruses Species 0.000 description 5
230000002411 adverse Effects 0.000 description 5
238000004108 freeze drying Methods 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
150000003432 sterols Chemical class 0.000 description 5
235000003702 sterols Nutrition 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000002562 urinalysis Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
235000015107 ale Nutrition 0.000 description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
230000034994 death Effects 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
230000002538 fungal effect Effects 0.000 description 4
230000012010 growth Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000008279 sol Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000009471 action Effects 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000009826 distribution Methods 0.000 description 3
230000002440 hepatic effect Effects 0.000 description 3
230000036571 hydration Effects 0.000 description 3
238000006703 hydration reaction Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
239000003415 peat Substances 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000003860 storage Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
HKLUUHOGFLPVLP-UHFFFAOYSA-N 3,5-dihydroxy-2-(2-hydroxyphenyl)-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1O HKLUUHOGFLPVLP-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
OWTYWMJVQZQWFH-JQTKPCACSA-N CE(20:1(11Z)) Chemical group C12CC[C@]3(C)C([C@H](C)CCCC(C)C)CCC3C2CC=C2[C@]1(C)CC[C@H](OC(=O)CCCCCCCCC\C=C/CCCCCCCC)C2 OWTYWMJVQZQWFH-JQTKPCACSA-N 0.000 description 2
241000222120 Candida <Saccharomycetales> Species 0.000 description 2
241000736839 Chara Species 0.000 description 2
241000784713 Cupido Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
101150039033 Eci2 gene Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
244000228957 Ferula foetida Species 0.000 description 2
241000726306 Irus Species 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010029155 Nephropathy toxic Diseases 0.000 description 2
101150034459 Parpbp gene Proteins 0.000 description 2
241000906446 Theraps Species 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
239000011717 all-trans-retinol Substances 0.000 description 2
235000019169 all-trans-retinol Nutrition 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000006399 behavior Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000001736 capillary Anatomy 0.000 description 2
150000001841 cholesterols Chemical class 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000007865 diluting Methods 0.000 description 2
MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000036541 health Effects 0.000 description 2
239000011261 inert gas Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
231100000417 nephrotoxicity Toxicity 0.000 description 2
230000007694 nephrotoxicity Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 2
230000008961 swelling Effects 0.000 description 2
QGVNJRROSLYGKF-UHFFFAOYSA-N thiobarbital Chemical compound CCC1(CC)C(=O)NC(=S)NC1=O QGVNJRROSLYGKF-UHFFFAOYSA-N 0.000 description 2
210000002105 tongue Anatomy 0.000 description 2
231100000041 toxicology testing Toxicity 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
230000035899 viability Effects 0.000 description 2
NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
PUMRUSBKNSBTAL-UHFFFAOYSA-N 3,4-dihydro-2h-chromene-2-carbaldehyde Chemical compound C1=CC=C2OC(C=O)CCC2=C1 PUMRUSBKNSBTAL-UHFFFAOYSA-N 0.000 description 1
241000331231 Amorphocerini gen. n. 1 DAD-2008 Species 0.000 description 1
241001535291 Analges Species 0.000 description 1
241000758250 Aspergillus fumigatus A1163 Species 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
101100427860 Brucella suis biovar 1 (strain 1330) ureE1 gene Proteins 0.000 description 1
101150000595 CLMP gene Proteins 0.000 description 1
101100048438 Caenorhabditis elegans unc-30 gene Proteins 0.000 description 1
241000581444 Clinidae Species 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
241001366015 Desis Species 0.000 description 1
101100382322 Drosophila melanogaster Acam gene Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000490229 Eucephalus Species 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
241001427367 Gardena Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
102000014702 Haptoglobin Human genes 0.000 description 1
108050005077 Haptoglobin Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000973623 Homo sapiens Neuronal growth regulator 1 Proteins 0.000 description 1
101100263201 Homo sapiens USP9X gene Proteins 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
241000976924 Inca Species 0.000 description 1
241001091433 Itea Species 0.000 description 1
241001527806 Iti Species 0.000 description 1
241001061269 Lestes Species 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100270435 Mus musculus Arhgef12 gene Proteins 0.000 description 1
101100537948 Mus musculus Trir gene Proteins 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
102100022223 Neuronal growth regulator 1 Human genes 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001163743 Perlodes Species 0.000 description 1
102100038603 Probable ubiquitin carboxyl-terminal hydrolase FAF-X Human genes 0.000 description 1
241001296096 Probles Species 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
101150107341 RERE gene Proteins 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
241000428533 Rhis Species 0.000 description 1
101000869583 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Oligo(A)/oligo(T)-binding protein Proteins 0.000 description 1
241000290149 Scapteriscus didactylus Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
241000219289 Silene Species 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
241000370991 Troides Species 0.000 description 1
206010046996 Varicose vein Diseases 0.000 description 1
206010058874 Viraemia Diseases 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
AVTXVDFKYBVTKR-DPAQBDIFSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] dihydrogen phosphate Chemical compound C1C=C2C[C@@H](OP(O)(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 AVTXVDFKYBVTKR-DPAQBDIFSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
QGLZXHRNAYXIBU-WEVVVXLNSA-N aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
101150039027 ampH gene Proteins 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
KTBKWJRLKSFWMY-UHFFFAOYSA-N azanium;2-chlorohept-1-enyl(hydroxy)arsinate Chemical compound [NH4+].CCCCCC(Cl)=C[As](O)([O-])=O KTBKWJRLKSFWMY-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
244000309466 calf Species 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
125000003901 ceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000001246 colloidal dispersion Methods 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229940003382 depo-medrol Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
PHTXVQQRWJXYPP-UHFFFAOYSA-N ethyltrifluoromethylaminoindane Chemical compound C1=C(C(F)(F)F)C=C2CC(NCC)CC2=C1 PHTXVQQRWJXYPP-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000010408 film Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
108010039551 hemorrhagic proteinase IV Proteins 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
230000003082 hepatotoxic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
101150085091 lat-2 gene Proteins 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
101150096059 lipC gene Proteins 0.000 description 1
235000015250 liver sausages Nutrition 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100001027 nephrosis Toxicity 0.000 description 1
208000009928 nephrosis Diseases 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
230000001379 nervous effect Effects 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000002577 ophthalmoscopy Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000003660 reticulum Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000007790 scraping Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000007873 sieving Methods 0.000 description 1
238000004513 sizing Methods 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000010959 steel Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012976 tarts Nutrition 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
101150019895 thiE gene Proteins 0.000 description 1
239000010409 thin film Substances 0.000 description 1
SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
101150008224 ureE gene Proteins 0.000 description 1
208000027185 varicose disease Diseases 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Inorganic Chemistry (AREA)
Biomedical Technology (AREA)
Nanotechnology (AREA)
Optics & Photonics (AREA)
Biophysics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

CA002113272A 1991-08-14 1992-08-12 Methode de traitement du sida par l'amphotericine b a toxicite reduite Abandoned CA2113272A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US74491591A	1991-08-14	1991-08-14
US744,915		1991-08-14

Publications (1)

Publication Number	Publication Date
CA2113272A1 true CA2113272A1 (fr)	1993-03-04

Family

ID=24994455

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002113272A Abandoned CA2113272A1 (fr)	1991-08-14	1992-08-12	Methode de traitement du sida par l'amphotericine b a toxicite reduite

Country Status (5)

Country	Link
EP (1)	EP0599977A1 (fr)
AU (1)	AU664857B2 (fr)
CA (1)	CA2113272A1 (fr)
IL (1)	IL102815A (fr)
WO (1)	WO1993003737A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2683723B1 (fr) *	1991-11-14	1995-05-19	Mayoly Spindler Laboratoires	Nouveaux medicaments antiviraux actifs sur le virus vih.
GB2290707A (en) *	1994-06-28	1996-01-10	Georgi Stankov	Pharmaceutical uses of Amphotericin B
GB2290708A (en) *	1994-06-28	1996-01-10	Georgi Stankov	Pharmaceutical uses of polyene macrolides
WO2002054868A2 (fr)	2000-12-21	2002-07-18	Inhale Therapeutic Syst	Apport pulmonaire d'agents antifongiques polyene
EP4322963A1 (fr) *	2021-04-16	2024-02-21	Pannonpharma Gyógyszergyártó Kft.	Traitement d'une infection virale avec un antibiotique macrolide polyénique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4822777A (en) *	1987-02-27	1989-04-18	Liposome Technology, Inc.	Amphotericin B/cholesterol sulfate composition
NZ223660A (en) *	1987-03-05	1990-11-27	Liposome Co Inc	Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity
US5032404A (en) *	1989-02-23	1991-07-16	Board Of Regents, The University Of Texas System	Lipsome-incorporation of polyenes

1992
- 1992-08-12 WO PCT/US1992/006788 patent/WO1993003737A1/fr not_active Ceased
- 1992-08-12 CA CA002113272A patent/CA2113272A1/fr not_active Abandoned
- 1992-08-12 AU AU24730/92A patent/AU664857B2/en not_active Ceased
- 1992-08-12 EP EP92918368A patent/EP0599977A1/fr not_active Ceased
- 1992-08-14 IL IL102815A patent/IL102815A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL102815A0 (en)	1993-01-31
EP0599977A1 (fr)	1994-06-08
AU2473092A (en)	1993-03-16
IL102815A (en)	1997-09-30
AU664857B2 (en)	1995-12-07
WO1993003737A1 (fr)	1993-03-04

Publication	Publication Date	Title
US20200338199A1 (en)	2020-10-29	Sodium chloride solution for drug reconstitution or dilution
US5466468A (en)	1995-11-14	Parenterally administrable liposome formulation comprising synthetic lipids
US4822777A (en)	1989-04-18	Amphotericin B/cholesterol sulfate composition
AU601848B2 (en)	1990-09-20	New anti-retroviral agents and delivery system
EP2676677A1 (fr)	2013-12-25	Préparation pharmaceutique d'anticorps anti-cd40 très concentrée
US5270053A (en)	1993-12-14	Parenterally administerable liposome formulation comprising synthetic lipid
DK168785B1 (da)	1994-06-13	Fremgangsmåde til fremstilling af en bærer ladet med lipofilt biologisk aktivt stof på basis af rekonstitueret LDL
CA2113272A1 (fr)	1993-03-04	Methode de traitement du sida par l'amphotericine b a toxicite reduite
CA2158140A1 (fr)	1994-09-29	Compositions pharmaceutiques stabilisees et leurs procedes de preparation
Shete et al.	2015	Mono-guanidine heterolipid based SMEDDS: A promising tool for cytosolic delivery of antineoplastics
FI104951B (fi)	2000-05-15	Menetelmä parenteraalisesti annettavan liposomikoostumuksen valmistamiseksi
KR20170083108A (ko)	2017-07-17	C형 간염에 대한 장기 작용 약학적 조성물
RU2275899C2 (ru)	2006-05-10	Структурированная эмульсия амфотерицина b с низкой токсичностью для парентерального введения и способ ее получения
US20190307683A1 (en)	2019-10-10	Ziyuglycoside II Polymer Micelle and Preparative Methods Thereof
D'Cruz et al.	2002	Two-year toxicity and carcinogenicity studies in B6C3F1 mice with 5-bromo-6-methoxy-5, 6-dihydro-3′-azidothymidine-5′-(p-bromophenyl) methoxyalaninyl phosphate (WHI-07), a novel anti-HIV and contraceptive agent
KR20160141367A (ko)	2016-12-08	액정 나노 입자, 이의 제조방법 및 친유성 약물이 봉입된 액정 나노입자를 함유하는 약물 전달 시스템
US10646440B2 (en)	2020-05-12	Sanguisorbigenin polymer micelle and preparative methods thereof
RU2821033C1 (ru)	2024-06-17	Раствор аминодигидрофталазиндиона натрия для внутривенного введения
CN117323410A (zh)	2024-01-02	一种多肽药物溶液制剂及其制备方法
HU224715B1 (en)	2006-01-30	Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus
CN112516125B (zh)	2024-03-15	酪氨酸在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用
US20240335387A1 (en)	2024-10-10	Lyophilized Vortioxetine Pamoate Powder for Injection and Preparation Method Therefor
RU2666148C1 (ru)	2018-09-06	Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
CN108175747A (zh)	2018-06-19	紫杉醇长循环热敏脂质体的制备方法
Branca et al.	1992	Biochemical and morphological observations on rat liver and kidneys six months after intravenous injection of a perfluorocompound emulsion

Legal Events

Date	Code	Title	Description
1994-01-11	EEER	Examination request
1997-08-12	FZDE	Discontinued